REBEL™
Platinum Chromium Coronary Stent System
OMEGA Trial*
- A prospective, single-arm, multi-center trial
- De novo lesions ≤ 28 mm in length and ≥ 2.25 mm to ≤ 4.50 mm in diameter
- Primary endpoint: Target Lesion Failure (TLF) at 9 months
- Analysis: Primary endpoint based on pre-defined performance goal of 21.2%
![OMEGA Trial graphic](https://www.bostonscientific.com/en-EU/products/stents-coronary/rebel/Clinical-Data/_jcr_content/maincontent-par/image_2.img.REBEL_bareMetalStent_chart.png)